HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife Reports Second Straight Year Of Record Sales And Of Costs Climbing Due To Pandemic

Executive Summary

Herbalife’s Asia-Pacific region led 2021 sales growth even as China sales continued to slide despite initiatives to boost business there. It reported record sales levels despite limits due to COVID-19 pandemic on shopping and other consumer activity while pandemic continues impacting supply and shipping costs and influenced 2022 earnings forecast.

You may also be interested in...



Herbalife Expects In-Person Events Will Spur Results From ‘Pandemic Cohort’ Of Distributors

Herbalife reported $1.3bn net sales in latest quarter, 11% off previous year on lack of in-person sales experiences from distributors recruited during pandemic.

US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results

Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.

Herbalife’s Asia-Pacific Region Stands Out As Most Others Fade In Year-Ago Comparison

Herbalife reports 46% growth in India fuels 11% sales increase to $393.5m for its Asia-Pacific region in Q3. Most regions had comparisons with year-ago quarter when pandemic stockpiling lifted sales.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS152243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel